CorMedix IncNASDAQ:CRMD
- LAST PRICE9.9100
- TODAY'S CHANGE (%)-0.0400 (-0.4020%)
- Bid / Lots9.8700/ 1
- Ask / Lots9.9600/ 5
- Open / Previous Close9.9500 / 9.9500
- Day Range
- 52 Week Range
- Volume17,216
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 7686 | 10.04 |
| 09:33 ET | 2285 | 10.0021 |
| 09:35 ET | 2303 | 9.91 |
Today
Nov 4, 2024
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones
8:30AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
DJ CorMedix Is Maintained at Buy by Needham, from 6:21AM ET on Thursday Oct 31, 2024 by Dow Jones
6:21AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
DJ CorMedix Down Over 15%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk, from 11:56AM ET on Wednesday Oct 30, 2024 by Dow Jones
11:56AM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ CorMedix 3Q Loss/Shr 5c >CRMD, from 7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 604.3M | -12.4x | --- |
Zevra Therapeutics Inc | 511.6M | -4.9x | --- |
Elite Pharmaceuticals Inc | 658.9M | -104.4x | --- |
Eton Pharmaceuticals Inc | 290.1M | -56.4x | --- |
Cipla Ltd | 14.4B | 0.0x | --- |
Incannex Healthcare Inc | 34.9M | -1.4x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Chief Executive Officer, Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Chief Clinical Strategy and Operations Officer
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Legal Officer and Corporate Secretary
- Beth Kaufman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $604.3M |
|---|---|
Revenue (TTM) | $12.3M |
Shares Outstanding | 60.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-0.80 |
Book Value | $1.28 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 49.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -415.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
